|Bid||161.45 x 800|
|Ask||161.49 x 1300|
|Day's range||160.44 - 161.81|
|52-week range||133.65 - 179.92|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||28.49|
|Earnings date||19 Oct 2021|
|Forward dividend & yield||4.24 (2.56%)|
|Ex-dividend date||23 Aug 2021|
|1y target est||187.17|
Johnson & Johnson (NYSE: JNJ) recently announced positive results from a phase 2 study of its RSV vaccine candidate. In this Motley Fool Live video recorded on Oct. 6, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not J&J set a high bar for Pfizer (NYSE: PFE) and GlaxoSmithKline (NYSE: GSK) to top.
Most stocks sink when the stock market itself plunges. Not only are their stocks available at a discount, but the lower share prices also allow you to lock in higher dividend yields. No one knows for sure whether the stock market will crash anytime soon.
A U.S. Food and Drug Administration (FDA) advisory committee has reviewed Johnson & Johnson's (NYSE: JNJ) data supporting boosters of its COVID-19 vaccine. The FDA gets the final say in the matter, though. In this Motley Fool Live video recorded on Oct. 6, Motley Fool contributors Keith Speights and Brian Orelli discuss J&J's prospects for authorization of boosters.